GI Society and CSIR Provide Input to PMPRB Consultations
On August 4, 2020, the Gastrointestinal Society and its partner charity, the Canadian Society of Intestinal Research, provided input on the Patented Medicine Prices Review Board (PMPRB) 2020 Draft Guidelines. These Guidelines are part of a broad set of regulatory changes sought by the PMPRB to modernize its price review process. In our submission, we advocate for a sustainable, fair, and transparent drug approval and reimbursement system in Canada that ensures Canadians maintain timely access to innovative medicines at affordable prices.
In its current form, the PMPRB Guidelines fail to address significant and pressing uncertainties that will likely affect patients’ access to lifesaving and life-prolonging medicines. It may also pose challenges for research and development via clinical trials and may negatively alter the availability of patient supports and compassionate access initiatives in the country.
This submission adds to our growing initiatives on engaging governments and stakeholders on the importance of access to innovative and life-extending therapies. To learn more about our key comments for consideration, read the letter we submitted to the PMPRB.
We also worked with the Medicine Access Coalition – BC (formerly the Better Pharmacare Coalition) to create a feedback document to the PMPRB. The Medicine Access Coalition – BC is also a member of the Best Medicines Coalition and we endorse the submissions provided by both of these organizations.
